Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posdinemab in early Alzheimer's disease
NL-OMON60958Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Posdinemab with Placebo (2 arms). Primary endpoint: Change from baseline on the iADRS total score at week 104. Started Sep 2021; status: completed.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60958.